Table 3.

Characteristics of 4 randomized trials comparing gemcitabine to gemcitabine plus other cytotoxic agents

Reference	Year	n	Treatment regimen	Stage IV (%)	Male (%)	PS 0–1 (%)
Oettle	2005	282	Gem 1000 mg/m2 for 3 of 4 wks	92	54	88
		283	Gem 1250 mg/m2 d1, 8 + Pemetrexed 500 mg/m2 d8 q 3 wks	90	60	85
Rocha Lima	2004	180	Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks	81	53	74
		180	Gem 1000 mg/m2 + Irinotecan 100 mg/m2 d1+8 q 3 wks	82	57	78
Stathopoulos	2006	70	Gem 900 mg/m2 for 3 of 4 wks	86	60	86
		60	Gem 900 mg/m2 d1, 8 + Irinotecan 300 mg/m2 d8, q 4 wks	78	65	87
O'Reilly	2004	174	Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks	78	57	52*
		175	Gem 1000 mg/m2 d1, 8 + Exatecan 2 mg/m2 d1+8 q 3 wks	79	53	51*

* KPS = 90–100%; PS = performance status;